# The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer.

**Tumor:** CPNM (cáncer de pulmón)
**Autores:** Mayenga M, Pedroso AR, Ferreira M et al
**Revista:** Breathe (Sheff) (2024)
**PMID:** 39534491 | **PMCID:** PMC11555582
**DOI:** [10.1183/20734735.0044-2024](https://doi.org/10.1183/20734735.0044-2024)
**Fuente:** PubMed Central (open access)

## Relevancia
CPNM resecable tras quimio-inmunoterapia neoadyuvante (CheckMate-816, NADIM, KEYNOTE-671): downstaging mediastínico (ypN0/N1), tasas de pCR ganglionar y supervivencia. Paralelo importante con mama: la conversión nodal patológica predice EFS/OS y orienta la extensión de la disección ganglionar.

## Abstract
Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemotherapy compared with chemotherapy alone. Furthermore, this article discusses the implications for future practice in resectable NSCLC and the need for future research.

## Acceso
Disponible en PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11555582/

---
*Datos de PubMed. Citar: doi 10.1183/20734735.0044-2024*
